**4. References**


Breast Cancer Stem Cells 285

[30] Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3, 730-7 (1997). [31] Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-

[32] McDermott, S. P. & Wicha, M. S. Targeting breast cancer stem cells. Mol Oncol 4, 404-19

[33] Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-52

[34] Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98, 10869-74 (2001). [35] Troester, M. A. et al. Gene expression patterns associated with p53 status in breast

[36] Lim, E. et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15, 907-13 (2009). [37] Chaffer, C. L. & Weinberg, R. A. Cancer cell of origin: spotlight on luminal progenitors.

[38] Nguyen, N. P. et al. Molecular biology of breast cancer stem cells: potential clinical

[39] Tanei, T. et al. Association of breast cancer stem cells identified by aldehyde

based chemotherapy for breast cancers. Clin Cancer Res 15, 4234-41 (2009). [40] Charafe-Jauffret, E. et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate

[41] Fogel, M. et al. CD24 is a marker for human breast carcinoma. Cancer Lett 143, 87-94

[42] Schindelmann, S. et al. Expression profiling of mammary carcinoma cell lines:

[43] Friedrichs, K. et al. CD44 isoforms correlate with cellular differentiation but not with

[44] Berner, H. S. & Nesland, J. M. Expression of CD44 isoforms in infiltrating lobular

[45] Kufe, D. W. et al. Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res 43, 851-7 (1983). [46] Abraham, B. K. et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be

[47] Duester, G. Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid. Eur J Biochem 267, 4315-24 (2000). [48] Sophos, N. A. & Vasiliou, V. Aldehyde dehydrogenase gene superfamily: the 2002

[49] Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-67 (2007). [50] Charafe-Jauffret, E. et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69, 1302-13 (2009). [51] Wright, M. H. et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10, R10 (2008).

prognosis in human breast cancer. Cancer Res 55, 5424-33 (1995).

carcinoma of the breast. Breast Cancer Res Treat 65, 23-9 (2001).

update. Chem Biol Interact 143-144, 5-22 (2003).

dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-

metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer

correlation of in vitro invasiveness with expression of CD24. Tumour Biol 23, 139-

associated with clinical outcome but may favor distant metastasis. Clin Cancer Res

401 (2004).

(2010).

(2000).

cancer. BMC Cancer 6, 276 (2006).

Cell Stem Cell 7, 271-2 (2010).

Res 16, 45-55 (2010).

(1999).

45 (2002).

11, 1154-9 (2005).

applications. Cancer Treat Rev 36, 485-91 (2010).


[7] Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F.

[8] Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res

[9] Kim, C. F. et al. Identification of bronchioalveolar stem cells in normal lung and lung

[10] Xin, L., Lawson, D. A. & Witte, O. N. The Sca-1 cell surface marker enriches for a

[11] O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-10 (2007). [12] Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell

[13] Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer

[14] Clarke, M. F. A self-renewal assay for cancer stem cells. Cancer Chemother Pharmacol

[15] Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by high-

[16] Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the

[17] Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat Rev Cancer 5,

[18] Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in

[19] Li, X. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl

[20] Woodward, W. A. et al. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 104, 618-23 (2007). [21] Wicha, M. S., Liu, S. & Dontu, G. Cancer stem cells: an old idea--a paradigm shift.

[22] Dalerba, P., Cho, R. W. & Clarke, M. F. Cancer stem cells: models and concepts. Annu

[23] Ginestier, C. et al. CXCR1 blockade selectively targets human breast cancer stem cells in

[24] Krishnamurthy, S. et al. Endothelial cell-initiated signaling promotes the survival and

[25] Liu, S. et al. Breast cancer stem cells are regulated by mesenchymal stem cells through

[26] Yu, F. et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell

[27] Shimono, Y. et al. Downregulation of miRNA-200c links breast cancer stem cells with

[28] Liu, C. et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis

[29] Yu, F. et al. MiR-30 reduction maintains self-renewal and inhibits apoptosis in breast

A 100, 3983-8 (2003).

cancer. Cell 121, 823-35 (2005).

Proc Natl Acad Sci U S A 102, 6942-7 (2005).

stem cells. Nature 414, 105-11 (2001).

throughput screening. Cell 138, 645-59 (2009).

cancer stem cells. Nature 458, 780-3 (2009).

Cancer Res 66, 1883-90; discussion 1895-6 (2006).

cytokine networks. Cancer Res 71, 614-24 (2011).

normal stem cells. Cell 138, 592-603 (2009).

vitro and in xenografts. J Clin Invest 120, 485-97 (2010).

by directly repressing CD44. Nat Med 17, 211-5 (2011).

tumor-initiating cells. Oncogene 29, 4194-204 (2010).

self-renewal of cancer stem cells. Cancer Res 70, 9969-78 (2010).

Cancer Inst 100, 672-9 (2008).

Rev Med 58, 267-84 (2007).

131, 1109-23 (2007).

DNA damage response. Nature 444, 756-60 (2006).

63, 5821-8 (2003).

104, 973-8 (2007).

275-84 (2005).

56 Suppl 1, 64-8 (2005).

Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S

prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis.

properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A


Breast Cancer Stem Cells 287

[70] Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors

[71] Ponti, D. et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with

[72] Zhang, M. et al. Identification of tumor-initiating cells in a p53-null mouse model of

[73] Pece, S. et al. Biological and molecular heterogeneity of breast cancers correlates with

[74] Karimi-Busheri, F., Rasouli-Nia, A., Mackey, J. R. & Weinfeld, M. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 12, R31 (2010). [75] Al-Hajj, M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol 19, 61-4 (2007). [76] Clarke, M. F. et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66, 9339-44 (2006). [77] Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties

[78] Santisteban, M. et al. Immune-induced epithelial to mesenchymal transition in vivo

[79] Hennessy, B. T. et al. Characterization of a naturally occurring breast cancer subset

[80] Carthew, R. W. Gene regulation by microRNAs. Curr Opin Genet Dev 16, 203-8 (2006). [81] Bushati, N. & Cohen, S. M. microRNA functions. Annu Rev Cell Dev Biol 23, 175-205

[82] Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-8 (2005). [83] Navarro, A. & Monzo, M. MicroRNAs in human embryonic and cancer stem cells.

[84] Chen, C. Z. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353, 1768-

[85] Takamizawa, J. et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64, 3753-6 (2004). [86] Yu, F. et al. MiR-30 reduction maintains self-renewal and inhibits apoptosis in breast

[87] Cimmino, A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl

[88] Bonci, D. et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting

[89] Bottoni, A. et al. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell

[90] Bandi, N. et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-

[91] Bhattacharya, R. et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer.

[92] DeSano, J. T. & Xu, L. MicroRNA regulation of cancer stem cells and therapeutic

[93] He, L. et al. A microRNA component of the p53 tumour suppressor network. Nature

[94] Ji, Q. et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric

dependent manner and are frequently deleted or down-regulated in non-small cell

enriched in epithelial-to-mesenchymal transition and stem cell characteristics.

generates breast cancer stem cells. Cancer Res 69, 2887-95 (2009).

from human glioblastoma. Cancer Res 64, 7011-21 (2004).

breast cancer. Cancer Res 68, 4674-82 (2008).

of stem cells. Cell 133, 704-15 (2008).

Cancer Res 69, 4116-24 (2009).

Yonsei Med J 51, 622-32.

Physiol 204, 280-5 (2005).

Cancer Res 69, 9090-5 (2009).

447, 1130-4 (2007).

tumor-initiating cells. Oncogene 29, 4194-204.

lung cancer. Cancer Res 69, 5553-9 (2009).

implications. Aaps J 11, 682-92 (2009).

cancer tumorspheres. BMC Cancer 8, 266 (2008).

multiple oncogenic activities. Nat Med 14, 1271-7 (2008).

Acad Sci U S A 102, 13944-9 (2005).

(2007).

71 (2005).

their cancer stem cell content. Cell 140, 62-73 (2010).

stem/progenitor cell properties. Cancer Res 65, 5506-11 (2005).


[52] Hwang-Verslues, W. W. et al. Multiple lineages of human breast cancer

[53] Goodell, M. A. et al. Dye efflux studies suggest that hematopoietic stem cells expressing

[54] Scharenberg, C. W., Harkey, M. A. & Torok-Storb, B. The ABCG2 transporter is an

[55] Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary

[56] Alvi, A. J. et al. Functional and molecular characterisation of mammary side population

[57] Clarke, R. B. et al. A putative human breast stem cell population is enriched for steroid

[58] Liu, B. Y., McDermott, S. P., Khwaja, S. S. & Alexander, C. M. The transforming activity

mammary progenitor cells. Proc Natl Acad Sci U S A 101, 4158-63 (2004). [59] Patrawala, L. et al. Side population is enriched in tumorigenic, stem-like cancer cells,

[60] Christgen, M. et al. Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. Mol Cell Biochem 306, 201-12 (2007). [61] Hiraga, T., Ito, S. & Nakamura, H. Side population in MDA-MB-231 human breast

[62] Zhou, S. et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of

[63] Zhou, S. et al. Bcrp1 gene expression is required for normal numbers of side population

[64] Petrides, M., Alivisatos, B. & Frey, S. Differential activation of the human orbital, mid-

[65] Schinkel, A. H. et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a

[66] Gao, Q., Geng, L., Kvalheim, G., Gaudernack, G. & Suo, Z. Identification of cancer stem-

[67] Kabashima, A. et al. Side population of pancreatic cancer cells predominates in TGF-

[68] Szotek, P. P. et al. Ovarian cancer side population defines cells with stem cell-like

[69] Reynolds, B. A. & Weiss, S. Clonal and population analyses demonstrate that an EGF-

cells in vivo. Proc Natl Acad Sci U S A 99, 12339-44 (2002).

visual stimuli. Proc Natl Acad Sci U S A 99, 5649-54 (2002).

human hematopoietic progenitors. Blood 99, 507-12 (2002).

stem/progenitor cells. Genes Dev 17, 1253-70 (2003).

receptor-positive cells. Dev Biol 277, 443-56 (2005).

cells. Breast Cancer Res 5, R1-8 (2003).

potential. Oncol Rep 25, 289-96 (2011).

e8377 (2009).

1337-45 (1997).

65, 6207-19 (2005).

Med 7, 1028-34 (2001).

491-502 (1994).

33, 175-81 (2009).

Sci U S A 103, 11154-9 (2006).

2771-9 (2009).

stem/progenitor cells identified by profiling with stem cell markers. PLoS One 4,

low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 3,

efficient Hoechst 33342 efflux pump and is preferentially expressed by immature

of Wnt effectors correlates with their ability to induce the accumulation of

whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res

cancer cells exhibits cancer stem cell-like properties without higher bone-metastatic

stem cells and is a molecular determinant of the side-population phenotype. Nat

stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic

ventrolateral, and mid-dorsolateral prefrontal cortex during the processing of

deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77,

like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol

beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer 124,

characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad

responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol 175, 1-13 (1996).


**Part 4** 

**Breast Cancer Gene Regulation** 

